



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration  
Rockville MD 20857

JUL 26 2001

SP 00P-1486/CP 1

Peter R. Miller DVM, MS  
Equi Aid Products, Inc.  
1517 West Knudsen Drive  
Phoenix, AZ 85027-1307

Dear Dr. Miller:

We refer to your suitability petition filed August 29, 2000, in which you requested permission to submit an abbreviated new animal drug application (ANADA) for a generic product that differs from an approved new animal drug in strength and dosage form. The approved pioneer product referenced in your petition is Merial LTD's Eqvalan® Paste (ivermectin) which is intended for use in horses, including mares, yearlings, and foals 6 to 8 weeks of age and older (NADA 134-314).

We informed you by telephone on January 11, 2001, that the letter faxed to you on December 27, 2000, approving your petition was inadvertently released before the Center's review of the petition was complete. We have now completed our evaluation of your petition and this letter is my ruling on it.

Your proposed product differs from the pioneer product in strength and dosage form. The pioneer product is an oral paste, whereas your proposed product is a packet containing five chewables that are administered via hand-feeding, top-dressing or mixing in a small amount of feed. The dosage of active ingredient per pound of body weight will be the same.

Changes in strength and dosage form are variances from the pioneer product which can be considered through a suitability petition, under section 512(n)(3) of the Federal Food, Drug, and Cosmetic Act. Pursuant to that provision, we are required to approve a petition for a new animal drug intended for use in a non-food animal unless we determine that investigations must be conducted to show the safety and effectiveness of the differences in the proposed generic product.

We have concluded that your suitability petition must be denied because studies must be conducted to show the effectiveness of the proposed dosage form in horses. Unlike the pioneer product, the proposed generic would be administered orally via hand-feeding, top-dressing, or mixing in a small amount of feed. We are concerned that foals may not consume an adequate amount of your proposed drug product when administered via feeding to get effective treatment.

However, you may wish to submit a hybrid application as described in our Seventh GADPTRA Policy Letter, dated March 20, 1991, which combines the elements of an ANADA and an NADA. The exact requirements of a hybrid application depend on the product for which the

6647 .01  
113  
MO:40

00P-1486

PDN1

application is submitted and may include a bioequivalence study and any additional studies required for approval of the application. Therefore, we recommend that you arrange a meeting with us to discuss the studies we believe will be necessary and that you submit protocols for our review before initiating any in vivo studies.


If you disagree with our denial of your suitability petition, you may petition for reconsideration of the denial following the procedures set forth in 21 CFR 10.33. Such petition should be submitted in accordance with § 10.20 in the format outlined in § 10.33. The petition must be based solely on the information and views contained in your original petition. The petition for reconsideration should be submitted no later than 30 days after the date of this denial of the suitability petition and must be filed with the Dockets Management Branch, Food and Drug Administration, HFA-305, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Please refer to docket number 00P-1486 in any submission regarding this original suitability petition.

If there is additional information not included as part of your original submission that you would like the agency to consider, you should submit a new petition under § 10.30 and include all necessary information to the Dockets Management Branch at the address noted above.

This action in response to your suitability petition does not alter the requirements for approval of a new animal drug, nor assure approval of the new animal drug.

If you have any questions regarding this letter, please call Dr. Allen Rudman, Deputy Director, Office of New Animal Drug Evaluation, (301) 827-0204.

Sincerely yours,



Claire M. Lathers, Ph.D., F.C.P.

Director

Office of New Animal Drug Evaluation  
Center for Veterinary Medicine

g-00



3 00 AUG 29 10 38

Lonnie Luther  
 DA, CVM HFC 102 Room 387  
 Generic Drug Branch  
 7500 Standish Place  
 Rockville, MD 20855

Dear Dr. Luther;

I have enclosed a Suitability Petition submission in reference to JINAD 10-664, ivermectin paste for horses. The reference (pioneer) product is Eqvalan® Paste for Horses; NADA 134-314 sponsored by Merial Ltd.

This submission is based on the Pre-ANADA Activities, ANADA Suitability Petition section in the second policy letter on the implementation of the Generic Animal Drug and Patent Term Restoration Act dated June 7, 1989. Specifically the Pre-ANADA Activities, ANADA Suitability Petition section in the second policy letter states:

“The filing of a Suitability Petition provides a means by which a firm may request permission to file an ANADA for a product which differs from the approved pioneer product.

The specific variances under the Act for which a Suitability Petition may be submitted are as follows:


1. Change of one ingredient in a combination product or premix
2. Change of a dosage form
3. Change of a strength of an ingredient
4. Change in route of administration
5. Change in use with other animal drugs in animal feed.”

Equi Aid is requesting permission to file an ANADA that differs from the pioneer in that the pioneer is a paste oral dosage form containing 1.87% ivermectin and the proposed product would be a chewable containing 22.7 mg ivermectin per chewable. Thus the proposed product would differ in dosage form, and strength.

The proposed generic product would contain animal feeds as inactive ingredients and would be administered via hand feeding, top-dress on feed or by mixing in the horses grain ration.

Sincerely;

Peter R. Miller DVM MS



00P. 1486  
 623-492-9190

1517 West Knudsen Drive  
 Phoenix, Arizona 85027

CPI

623-492-9385 (FAX)

MEMO

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE  
FOOD AND DRUG ADMINISTRATION  
CENTER FOR VETERINARY MEDICINE

DATE: 7/26/01

FROM: Animal Scientist  
Quality Assurance Support Staff, HFV-102

SUBJECT: Suitability Petition Response for Display.

TO: Lyle Jaffe, HFA-305, 5630 Fishers Lane, rm. 1061, Rockville, MD  
Dockets Management Branch, 301 827-6860 (V)

6646 '01 JUL 30 AM:40

The attachment is the Center for Veterinary Medicine's letter related to Suitability Petition SP 00P-1486CP 1, submitted by Equi Aid Product, Inc. filed as a **Suitability Petition**. We are forwarding a copy for public display with the petition.

If you have any questions, please call me at 827-0211, or FAX 827-4317.

Thank you.

*SHS* 7/27/01  
Sam Hansard, Ph.D.

Attachment

Samuel Hansard, Ph.D.  
FDA/CVM/ONADE/QASS/HFV-102  
7500 Standish Place MPN II 384  
Rockville, MD 20855  
(301) 827-0211  
(301) 827-4317 fax  
shansard@cvm.fda.gov